Last reviewed · How we verify

Chronic antibioticrefractory ileal pouchitis — Treatment Landscape & Competitive Intelligence

Chronic antibioticrefractory ileal pouchitis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chronic antibioticrefractory ileal pouchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Entyvio vedolizumab Takeda Integrin Receptor Antagonist [EPC] Integrin alpha-4/beta-7

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Takeda · 1 drug in Chronic antibioticrefractory ileal pouchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chronic antibioticrefractory ileal pouchitis:

Cite this brief

Drug Landscape (2026). Chronic antibioticrefractory ileal pouchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chronic-antibioticrefractory-ileal-pouchitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing